Cardiac regeneration gene therapy involves the use of specific genes to stimulate the regeneration of damaged heart tissue. The cardiac regeneration laboratory is developing several new gene therapies to regenerate the heart based on direct cardiac reprogramming.
Our animal studies have shown promising results, with improved cardiac function and tissue regeneration observed after gene delivery. We are currently exploring different delivery methods, including viral vectors and non-viral methods, to safely and efficiently introduce the therapeutic genes into the heart. We are also investigating the most effective combination of genes and the optimal timing for gene delivery.
Furthermore, studies are underway to better comprehend the underlying molecular mechanisms involved in the direct reprogramming process, with the goal of developing targeted and personalized therapies for patients with heart disease.
Selected Publications
- p63 Silencing induces reprogramming of cardiac fibroblasts into cardiomyocyte-like cells
- Heart regeneration: The endothelial cell comes first
- Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on
- Reciprocity of Action of Increasing Oct4 and Repressing p53 in Transdifferentiation of Mouse Embryonic Fibroblasts into Cardiac Myocytes
- Triplet polycistronic vectors encoding Gata4, mef2c, and Tbx5 enhances post-infarct improvement compared with singlet vectors
- In vivo cardiac cellular reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with VEGF
- Histone Demethylase LSD1 is Involved in SALL4 Mediated Transcriptional Repression in Hematopoietic Stem Cells
